P Nos

Summary

Country: Spain

Publications

  1. ncbi [Budesonide in inflammatory bowel disease: a meta-analysis]
    P Nos
    Servicio de Medicina Digestiva Hospital La Fe Valencia
    Med Clin (Barc) 116:47-53. 2001
  2. ncbi [Factors influencing the decision to administer systemic corticosteroids in Crohn's disease]
    P Nos
    Servicio de Medicina Digestiva, Hospital La Fe, Valencia, Spain
    Gastroenterol Hepatol 27:444-9. 2004
  3. ncbi [Sciatica secondary to a presacral abscess as the first manifestation of Crohn's disease]
    V Aguilera
    Servicio de Medicina Digestiva, Hospital Universitario La Fe, Valencia, Espana
    Gastroenterol Hepatol 25:505-7. 2002
  4. ncbi HLA antigens and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease
    A García Herola
    Servicio de Medicina Digestivo Hospital Universitario La Fe Valencia Spain
    Rev Esp Enferm Dig 95:760-4, 755-9. 2003
  5. ncbi Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease
    G Bastida
    Gastroenterology Unit, La Fe Hospital, Valencia, Spain
    Aliment Pharmacol Ther 22:775-82. 2005
  6. ncbi Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    E Domenech
    Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    Aliment Pharmacol Ther 22:1107-13. 2005
  7. ncbi [Cyclosporine in ulcerative colitis flares]
    P Nos
    Gastroenterol Hepatol 28:629-31. 2005
  8. pmc Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease
    B Beltran
    Gut 55:1670-1. 2006

Collaborators

  • Guillermo Bastida
  • Miquel A Gassull
  • J Ponce
  • B Beltran
  • E Domenech
  • M Hoyos
  • A García Herola
  • V Aguilera
  • M Iborra
  • E Cabre
  • E Garcia-Planella
  • I Bernal
  • J Hinojosa
  • N Puig
  • E Carmona
  • J R Moles
  • J Hinijosa
  • J Berenguer
  • J M Sanchez-Cuenca
  • F Calvo
  • A Molla
  • R Esteban

Detail Information

Publications8

  1. ncbi [Budesonide in inflammatory bowel disease: a meta-analysis]
    P Nos
    Servicio de Medicina Digestiva Hospital La Fe Valencia
    Med Clin (Barc) 116:47-53. 2001
    ..The aim of the study was to evaluate its efficacy in inducing and maintaining remission of CD in oral administration and in inducing endoscopic and histologic remission in distal UC when was given as enema...
  2. ncbi [Factors influencing the decision to administer systemic corticosteroids in Crohn's disease]
    P Nos
    Servicio de Medicina Digestiva, Hospital La Fe, Valencia, Spain
    Gastroenterol Hepatol 27:444-9. 2004
    ..The objective of this study is to determine which clinical and laboratory parameters are associated with the therapeutic decision to administer corticosteroids during the course of the disease...
  3. ncbi [Sciatica secondary to a presacral abscess as the first manifestation of Crohn's disease]
    V Aguilera
    Servicio de Medicina Digestiva, Hospital Universitario La Fe, Valencia, Espana
    Gastroenterol Hepatol 25:505-7. 2002
    ..Complementary investigations confirmed the suspected diagnosis of Crohn's disease and showed presacral abscess. Treatment was surgical...
  4. ncbi HLA antigens and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease
    A García Herola
    Servicio de Medicina Digestivo Hospital Universitario La Fe Valencia Spain
    Rev Esp Enferm Dig 95:760-4, 755-9. 2003
    ....
  5. ncbi Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease
    G Bastida
    Gastroenterology Unit, La Fe Hospital, Valencia, Spain
    Aliment Pharmacol Ther 22:775-82. 2005
    ..The incidence of thiopurine-induced hepatotoxicity in patients with inflammatory bowel disease varies in different studies...
  6. ncbi Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    E Domenech
    Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    Aliment Pharmacol Ther 22:1107-13. 2005
    ..Few data are available regarding the evolution of Crohn's disease after discontinuing a successful course of infliximab...
  7. ncbi [Cyclosporine in ulcerative colitis flares]
    P Nos
    Gastroenterol Hepatol 28:629-31. 2005
  8. pmc Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease
    B Beltran
    Gut 55:1670-1. 2006